Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

SHA:688266 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	1,640	810.48	532.95	386.44	302.31	190.36
Revenue Growth	145.58%	52.07%	37.91%	27.83%	58.81%	588.19%
Gross Profit Gross Profit Growth	1,532	728.51	495.23	355.02	274.78	183.26
Operating Income Operating Income Growth	483.68	-242.84	-217.02	-397.45	-538.06	-505.91
Net Income Net Income Growth	549.87	-162.95	-137.83	-278.58	-457.33	-451
Earnings Per Share EPS Growth	2.07	-0.62	-0.52	-1.09	-1.91	-1.88
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025
Period Ending	Mar 31, 2026	Dec 31, 2025
China China Growth	1,540	802.64
Overseas Overseas Growth	-	7.55
Total Total Growth	1,548	810.19

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	2,470	2,031	2,194	2,247	1,046	1,202
Total Debt Total Debt Growth	812.94	1,133	1,039	888.35	547.8	223.57
Net Cash (Debt) Net Cash Growth	1,657	898.42	1,155	1,358	498.18	978.32
Net Cash Growth	63.57%	-22.21%	-14.97%	172.65%	-49.08%	-36.78%
Net Cash Per Share Net Cash Per Share Growth	6.25	3.42	4.36	5.31	2.08	4.08

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	796.75	-28.78	38.2	-232.75	-370.34	-454.62
Capital Expenditures CapEx Growth	-151.17	-181.47	-95.69	-62.6	-88.62	-70.74
Free Cash Flow Free Cash Flow Growth	645.58	-210.25	-57.49	-295.35	-458.97	-525.36
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	93.43%	89.89%	92.92%	91.87%	90.89%	96.27%
Operating Margin	29.49%	-29.96%	-40.72%	-102.85%	-177.98%	-265.77%
Pretax Margin	33.37%	-20.81%	-29.09%	-77.40%	-161.41%	-244.35%
Profit Margin	33.52%	-20.11%	-25.86%	-72.09%	-151.28%	-236.92%
FCF Margin	39.36%	-25.94%	-10.79%	-76.43%	-151.82%	-275.98%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Forward PE	64.18	35.51	35.51	35.51	35.51	-
PS Ratio	19.71	30.28	30.95	36.26	33.11	74.13

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error